Drug Profile


Alternative Names: GLS4; Morphothiadin; Morphothiadine mesilate; Morphothiadine mesylate

Latest Information Update: 17 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator HEC Pharm
  • Class Antivirals; Mesylates
  • Mechanism of Action Hepatitis B virus replication inhibitors; Viral core protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Hepatitis B

Most Recent Events

  • 20 Oct 2017 Interim pharmacodynamics data from preclinical study in Hepatitis B presented at the 68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2017)
  • 25 Aug 2016 Phase-II/III clinical trials in Hepatitis B in China (PO) (HEC Pharm pipeline, August 2016)
  • 11 Jan 2016 Phase-II development is ongoing in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top